Schuyler Vinzant

Schuyler Vinzant joined Adial Pharmaceuticals in 2020 and serves as Vice President of Development. Prior to joining Adial, Mr. Vinzant has over 20 years of experience in obtaining global regulatory approvals and managing clinical trials. Most recently Mr. Vinzant was Sr. Director of Clinical Operations and Regulatory Affairs at Krystal Biotech (NASDAQ: KRYS), a company developing gene therapies for rare diseases, where he oversaw the successful IND submission early phase clinical trial conduct of topical gene therapy. From 1999 to the present-day Mr. Vinzant served in several leadership positions of increasing levels of responsibility in the pharmaceutical and biotech industries. He has materially contributed to the growth of multiple start-ups including the management of the multi-protocol clinical program for the FDA-approved ADHD drug Vyvanse®, which resulted in a $2.6B acquisition of New River Pharmaceuticals from Shire Plc. He has overseen clinical and regulatory operations for small molecules and biologics across a variety of indications including multiple oncology indications, pain, ADHD, multiple rare diseases, and autoimmune diseases. Mr. Vinzant received a BS in Biology from George Mason University.